{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:33:18Z","timestamp":1760189598286},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bulcan.2017.06.020","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T00:46:48Z","timestamp":1511484408000},"page":"S112-S120","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S","title":["Allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans la lymphome de Hodgkin, le lymphome du manteau et autres h\u00e9mopathies lympho\u00efdes rares\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"104","author":[{"given":"Jordan","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Gac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Delage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lewalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0310","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2017.06.020_bib0315","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bbmt.2015.05.007","article-title":"Impact of pretransplantation (18)F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2017.06.020_bib0320","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.bbmt.2016.03.034","article-title":"Impact of pretransplantation (18)F-fluorodeoxyglucose-positron emission tomography on survival outcomes after T cell-depleted allogeneic transplantation for Hodgkin lymphoma","volume":"22","author":"Reyal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0325","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1148\/radiol.2015142556","article-title":"Prognostic value of FDG PET\/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma","volume":"277","author":"Ulaner","year":"2015","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0330","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2017.06.020_bib0335","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pretransplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.bulcan.2017.06.020_bib0340","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11S","key":"10.1016\/j.bulcan.2017.06.020_bib0345","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2017.06.020_bib0350","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","article-title":"Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant","volume":"98","author":"Van Den Neste","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.bulcan.2017.06.020_bib0355","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2017.06.020_bib0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2017.06.020_bib0365","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced-intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2017.06.020_bib0370","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin's lymphoma responding to prior salvage therapy","volume":"97","author":"Devillier","year":"2012","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.bulcan.2017.06.020_bib0375","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","article-title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2017.06.020_bib0380","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","article-title":"Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10044","key":"10.1016\/j.bulcan.2017.06.020_bib0385","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0390","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2017.06.020_bib0395","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.06.020_bib0400","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"10020","key":"10.1016\/j.bulcan.2017.06.020_bib0405","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2017.06.020_bib0410","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2017.06.020_bib0415","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2016-0146","article-title":"Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review","author":"Kharfan-Dabaja","year":"201612222631","journal-title":"Future Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2017.06.020_bib0420","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D.\u00a0Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2017.06.020_bib0425","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0430","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ejh.12442","article-title":"Role of allogeneic stem cell transplantation in mantle cell lymphoma","volume":"94","author":"Cohen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.bulcan.2017.06.020_bib0435","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bmt.2015.156","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era","volume":"50","author":"Mussetti","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.bulcan.2017.06.020_bib0440","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after non-myeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0445","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2017.06.020_bib0450","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.bulcan.2017.06.020_bib0455","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 fran\u00e7aise de greffe de moelle et de th\u00e9rapie cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0460","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/bmt.2014.243","article-title":"Graft-versus-T cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T cell lymphoma in relapse after allogeneic transplantation","volume":"50","author":"Mamez","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2017.06.020_bib0465","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2017.06.020_bib0470","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/leu.2012.321","article-title":"Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas with central review of pathology","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0475","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2017.06.020_bib0480","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem cell transplantation for peripheral T cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.06.020_bib0485","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bulcan.2017.06.020_bib0490","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0495","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0500","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","article-title":"Allogeneic haematopoietic cell transplantation after non-myeloablative conditioning in patients with T cell and natural killer-cell lymphomas","volume":"150","author":"Shustov","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0505","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/bmt.2017.12","article-title":"GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses","volume":"52","author":"Sellner","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0510","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1600-0609.2001.00377.x","article-title":"Treatment of T-prolymphocytic leukemia with non-myeloablative allogeneic stem cell transplantation","volume":"66","author":"Garderet","year":"2001","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.bulcan.2017.06.020_bib0515","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1705294","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission","volume":"37","author":"de Lavallade","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0520","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2017.06.020_bib0525","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium","volume":"26","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bulcan.2017.06.020_bib0530","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.12430","article-title":"Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French Society for Stem Cell Transplantation (SFGM-TC)","volume":"94","author":"Guillaume","year":"2015","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2017.06.020_bib0535","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2015.01.003","article-title":"Hematopoietic stem cell transplantation for primary cutaneous gammadelta T cell lymphoma and refractory subcutaneous panniculitis-like T cell lymphoma","volume":"72","author":"Gibson","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.bulcan.2017.06.020_bib0540","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/1346-8138.13199","article-title":"Hematopoietic stem cell transplantation for cutaneous T cell lymphoma: summary of 11 cases from two facilities in Japan and Brazil","volume":"43","author":"Oka","year":"2016","journal-title":"J Dermatol"},{"issue":"12","key":"10.1016\/j.bulcan.2017.06.020_bib0545","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0550","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0609.2007.00814.x","article-title":"Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion","volume":"78","author":"Todisco","year":"2007","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0555","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D.\u00a0Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.bulcan.2017.06.020_bib0560","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following non-myeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2017.06.020_bib0565","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bmt.1705977","article-title":"Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation","volume":"41","author":"Thomson","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2017.06.020_bib0570","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2008.11.011","article-title":"Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"15","author":"Devetten","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0575","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bulcan.2017.06.020_bib0580","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2008.12.506","article-title":"Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma","volume":"15","author":"Castagna","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0585","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bulcan.2017.06.020_bib0590","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","article-title":"Impact of disease status and stem cell source on the results of reduced-intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"98","author":"Marcais","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bulcan.2017.06.020_bib0595","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","article-title":"Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma","volume":"49","author":"Raiola","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2017.06.020_bib0600","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs. HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2017.06.020_bib0605","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2016.349","article-title":"Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"52","author":"Gauthier","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.bulcan.2017.06.020_bib0305","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117302771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117302771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:24:10Z","timestamp":1719620650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455117302771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0007455117302771"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.06.020","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans la lymphome de Hodgkin, le lymphome du manteau et autres h\u00e9mopathies lympho\u00efdes rares\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}